Concepedia

Yumeng Wang

YW

Statistics

Publications

2

Citations

79

H-Index

2

Active since

2022

Affiliations

Regend Therapeutics (China)(Current)

Yumeng Wang is an author at Regend Therapeutics (China) specializing in tumor immunology, cancer immunotherapy, and resistance to checkpoint inhibitors.

ORCID

Publications per year

2022–2024

2

Publications

2

Targeting CD96 overcomes PD-1 blockade resistance by enhancing CD8+ TIL function in cervical cancer

Yumeng Wang, Congwen Wang, Junjun Qiu et al. · Journal for ImmunoTherapy of Cancer · 2022 · 68 citations · Full text

, , +17

Claudin18.2-targeted chimeric antigen receptor T cell-therapy for patients with gastrointestinal cancers: Final results of CT041-CG4006 phase 1 trial.

Changsong Qi, Chang Liu, Jifang Gong et al. · Journal of Clinical Oncology · 2024 · 11 citations

, , +17

1–2 of 2